

dfw

Docket No. TPI5020US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Hongming Chen

Serial No. : 10/700,773

Art Unit: 1743

Filed : November 4, 2003

Examiner: Paul S.H. Hyun

For : ANALYSIS OF PHARMACEUTICAL SOLUBILITY AND STABILITY


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

10/12/06

(Date of Deposit)

Paul Burgess

(Name of applicant, assignee, or Registered Representative)



(Signature)

10/12/06

(Date of Signature)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure Statement mailed on June 7, 2004.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this

information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.


☒ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a) (2).

☒ There are no listed references which are not in the English language.

☒ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to
Deposit Account No. 10-0750/TPI0020/PB. This form is submitted
in triplicate.

Respectfully submitted,



Paul Burgess

Reg. No. 53,852

Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(781) 674-7816

DATED: 10/12/2006



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 1 of 1	Application Number	10/700,773
	Filing Date	November 4, 2003
	First Named Inventor	Hongming Chen
	Group Art Unit	1743
	Examiner Name	Paul S.H. Hyun
	Attorney Docket Number	TPI5020US

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
		6,109,717		Kane et al.	08-29-2000	
		5,699,934		Kolcun et al.	12-23-1997	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵				
		WO	01/51919		Transform Pharmaceuticals, Inc. et al.	07-19-2001		
		WO	03/02339 4		Phares Pharmaceutical Research N.V. et al.	03-20-2003		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		D'ANTONA, P. et al., "Rheologic and NMR Characterization of Monoglyceride-based Formulations", Journal of Biomedical Materials Research, Vol. 52, No. 1, October 2000, pp. 40-52	
		LIPINSKI, C.A., "Drug-Like Properties and The Causes of Poor Solubility and Poor Permeability", Journal of Pharmacological and Toxicological Methods, Vol. 44, No. 1, 2000, pp. 235-249	
		BEVAN, C.D. et al., "A high-throughput screening method for the determinations of aqueous drug solubility using laser nephelometry in microtiter plates", Analytical Chemistry, American Chemical Society, Vol. 72, No. 8, April 15, 2000	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Page 1 of 1